ILMN - Illumina, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Illumina, Inc.

5200 Illumina Way
San Diego, CA 92122
United States
858-202-4500
http://www.illumina.com

SectorHealthcare
IndustryDiagnostics & Research
Full Time Employees6,200

Key Executives

NameTitlePayExercisedYear Born
Mr. Jay T. FlatleyExec. ChairmanN/AN/A1953
Mr. Francis A. deSouzaCEO, Pres & DirectorN/AN/A1971
Mr. Sam A. SamadCFO & Sr. VP1.18MN/A1970
Mr. Omead OstadanExec. VP of Operations and ProductsN/AN/A1972
Mr. Marc A. StapleyExec. VP of Strategy & Corp. Devel.N/AN/A1970
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Illumina, Inc. provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array. The company also provides various library preparation and sequencing kits to simplify workflows and accelerate analysis; and genome sequencing, genotyping, and noninvasive prenatal testing, as well as products support services. It serves genomic research centers, academic institutions, government laboratories, and hospitals; and pharmaceutical, biotechnology, agrigenomics, and commercial molecular diagnostic laboratories, as well as consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. It operates in North America, Europe, Latin America, the Asia-Pacific region, the Middle East, and South Africa. The company has a strategic partnership with Loxo Oncology, Inc. to develop and commercialize a multi-gene panel for broad tumor profiling; and strategic collaboration with Bristol-Myers Squibb Company. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.

Corporate Governance

Illumina, Inc.’s ISS Governance QualityScore as of December 1, 2018 is 6. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 6; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.